Bliss GVS Pharma Ltd's Q4FY25 Quarterly Results

Result Summary

• Bliss GVS Pharma Ltd reported a 9.7% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 8.5%.
• Its expenses for the quarter were down by 5.7% QoQ and 5.3% YoY.
• The net profit decreased 119.1% QoQ and decreased 242.2% YoY.
• The earnings per share (EPS) of Bliss GVS Pharma Ltd declined at 0.9 during Q4FY25.

Financial Statments for Q4FY25

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Bliss GVS Pharma Ltd is a pharmaceutical company that primarily focuses on the research, development, manufacturing, and marketing of pharmaceutical products. The company operates within the pharmaceutical industry, a sector known for its significant investments in research and development to create innovative healthcare solutions. Bliss GVS Pharma is recognized for producing a range of products, including formulations such as tablets, creams, and ointments, which are distributed both domestically and internationally. At this time, there are no specific recent major developments available for Bliss GVS Pharma Ltd.

Revenue

In the fourth quarter of the fiscal year 2025 (Q4FY25), Bliss GVS Pharma Ltd reported a total income of ₹203.73 crores. This represents a decrease of 9.7% from the previous quarter (Q3FY25), during which the company recorded a total income of ₹225.68 crores. However, when compared on a year-over-year basis, there was an increase of 8.5% from the fourth quarter of the fiscal year 2024 (Q4FY24), where the total income was ₹187.76 crores. This data highlights the fluctuations in revenue across quarters and the growth over the fiscal year.

Profitability

For Q4FY25, Bliss GVS Pharma Ltd faced a challenging financial period, with a reported Profit Before Tax (PBT) of -₹3.95 crores, contrasting sharply with the profit of ₹36.42 crores in Q3FY25. This marks a significant quarter-over-quarter decline of 110.8%. On a year-over-year basis, however, there was an increase of 426.7% in PBT compared to -₹0.75 crores in Q4FY24. The company also experienced a Profit After Tax (PAT) of -₹4.92 crores in Q4FY25, down notably from ₹25.80 crores in Q3FY25, reflecting a decrease of 119.1% quarter-over-quarter. Year-over-year, PAT showed a decline of 242.2% from ₹3.46 crores in Q4FY24. Earnings Per Share (EPS) followed a similar trend, with a decrease to -₹0.90 in Q4FY25 from ₹2.30 in Q3FY25, and a year-over-year decline of 400% from ₹0.30 in Q4FY24.

Operating Metrics

The total expenses for Bliss GVS Pharma Ltd in Q4FY25 were ₹178.48 crores, which is a reduction of 5.7% from ₹189.26 crores in Q3FY25. Compared to Q4FY24, total expenses decreased by 5.3% from ₹188.50 crores. The tax expense for Q4FY25 was ₹0.96 crores, significantly lower than ₹10.62 crores in Q3FY25, reflecting a 91.0% quarter-over-quarter decrease. Year-over-year, the tax expense increased by 122.7% from a negative tax expense of -₹4.22 crores in Q4FY24. These metrics underscore the financial adjustments and changes in tax liabilities the company experienced during the analyzed periods.